Inebilizumab Human Monoclonal Antibody
Inebilizumabis a research-grade recombinant antibody targeting CD19. Produced in mammalian cells with native-like glycosylation. Highlights Research Grade: For PK/PD studies, assay development, and ADA research. Native Glycosylation: Mammalian expression ensures native-like patterns.
Product Specifications
Product Name Alternative
CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4
UniProt
P15391
Reactivity
Human
Clonality
Monoclonal
Conjugation
Unconjugated
Purification
Protein A/G purified from cell culture supernatant.
Concentration
Lot dependent
Purity
>95% purity as determined by SDS-PAGE.
Form
Liquid
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Tested Applications
ELISA, FA, FACS, In vivo
Host or Source
Human Humanized
Preservative
0.01M PBS, pH 7.4.
Isotype
IgG1-kappa
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Caenorhabditis Elegans sra-39 Protein (aa 1-375)
TAF172 (BTAF1) Human shRNA Lentiviral Particle (Locus ID 9044)
